Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ipca Laboratories Limited (IPCALAB.NS)
INR1,880.00
+39.60 (+2.15%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
125, Kandivli Industrial Estate 400067
Mumbai, MH, IN
Mumbai, MH, IN
CEO
Pranay Godha
Website
ipca.com
IPO
1996-01-01
ISIN INE571A01038
Also trades on
Bombay Stock Exchange · IPCALAB.BO (INR)
National Stock Exchange of India · IPCALAB.NS (INR)
Description
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,880.00
+39.60 (+2.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
271.0K
Beta
0.06
Float Shares
139.28M
Free Float %
54.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.92% | -7.14% | -2.35% | -2.22% | +2.88% | +5.36% | +5.59% | +113.28% | +44.40% | +595.51% | +15,975.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,880.00
DCF (Unlevered)
591.50
-68.5%
DCF (Levered)
1,141.34
-39.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
82% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 9 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.74
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.9% ★ Q1'26: +6.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+54.7% ★ Q1'26: +341.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.4% Q1'26: +13.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.2% ★ Q1'26: +15.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.9% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.41× ★ Q1'26: 0.42× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 1996 actual |
Mar 1997 actual |
Mar 1998 actual |
Mar 1999 actual |
Mar 2000 actual |
Mar 2001 actual |
Mar 2005 actual |
Mar 2006 actual |
Mar 2007 actual |
Mar 2008 actual |
Mar 2009 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 10 EPS Ana. |
Mar 2027 8 Rev. Ana. 8 EPS Ana. |
Mar 2028 15 Rev. Ana. 15 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.21B
est.
|
14.61B
est.
|
30.80B
est.
|
38.92B
est.
|
41.12B
est.
|
46.14B
est.
|
6.79B
est: 7.23B (-6.1%)
|
7.60B
est: 7.70B (-1.3%)
|
9.39B
est: 9.31B (+0.9%)
|
10.51B
est: 11.01B (-4.5%)
|
12.84B
est: 12.70B (+1.1%)
|
15.60B
est: 15.65B (-0.3%)
|
19.00B
est: 18.72B (+1.5%)
|
23.59B
est: 23.66B (-0.3%)
|
28.13B
est: 28.26B (-0.5%)
|
32.82B
est: 33.34B (-1.6%)
|
31.44B
est: 31.69B (-0.8%)
|
28.67B
est: 29.26B (-2.0%)
|
31.56B
est: 31.80B (-0.8%)
|
32.85B
est: 32.26B (+1.8%)
|
37.75B
est: 36.93B (+2.2%)
|
46.50B
est: 45.28B (+2.7%)
|
54.21B
est: 55.59B (-2.5%)
|
58.31B
est: 58.51B (-0.3%)
|
62.48B
est: 62.12B (+0.6%)
|
77.06B
est: 82.13B (-6.2%)
|
89.41B
est: 89.36B (+0.1%)
|
96.55B
95.72B – 97.42B
+8.0% YoY
|
107.40B
103.74B – 109.33B
+11.2% YoY
|
120.58B
115.63B – 125.07B
+12.3% YoY
|
| EBITDA |
441.30M
est.
|
934.58M
est.
|
1.97B
est.
|
5.93B
est.
|
149.26M
est.
|
223.81M
est.
|
1.22B
est: 35.15M (+3,362.9%)
|
1.13B
est: 1.51B (-25.3%)
|
2.06B
est: 1.82B (+13.1%)
|
2.28B
est: 1.92B (+18.9%)
|
1.90B
est: 2.38B (-20.2%)
|
3.49B
est: 752.13M (+363.8%)
|
4.26B
est: 3.60B (+18.4%)
|
4.68B
est: 5.37B (-13.0%)
|
6.42B
est: 4.18B (+53.8%)
|
8.34B
est: 5.42B (+53.8%)
|
5.30B
est: 6.43B (-17.6%)
|
3.25B
est: 4.91B (-33.7%)
|
4.26B
est: 2.53B (+68.5%)
|
4.50B
est: 4.54B (-0.8%)
|
7.08B
est: 5.33B (+32.7%)
|
9.38B
est: 8.94B (+5.0%)
|
15.07B
est: 10.82B (+39.3%)
|
12.75B
est: 12.08B (+5.6%)
|
9.46B
est: 13.96B (-32.2%)
|
12.64B
est: 17.10B (-26.1%)
|
16.67B
est: 17.96B (-7.2%)
|
20.10B
19.93B – 20.28B
+11.9% YoY
|
22.36B
21.60B – 22.76B
+11.2% YoY
|
25.10B
24.07B – 26.04B
+12.3% YoY
|
| EBIT |
354.73M
est.
|
2.45B
est.
|
5.17B
est.
|
15.56B
est.
|
391.90M
est.
|
471.70M
est.
|
1.03B
est: 74.09M (+1,283.5%)
|
877.60M
est: 1.21B (-27.6%)
|
1.77B
est: 1.47B (+20.6%)
|
1.96B
est: 1.96B (-0.3%)
|
1.50B
est: 1.57B (-4.3%)
|
3.02B
est: 2.67B (+13.1%)
|
3.70B
est: 3.33B (+11.3%)
|
4.00B
est: 3.92B (+2.1%)
|
5.58B
est: 5.32B (+4.9%)
|
7.34B
est: 6.35B (+15.5%)
|
3.54B
est: 6.94B (-48.9%)
|
1.69B
est: 3.19B (-47.1%)
|
2.60B
est: 1.84B (+41.2%)
|
2.79B
est: 2.62B (+6.4%)
|
5.31B
est: 3.20B (+65.8%)
|
7.42B
est: 6.50B (+14.1%)
|
13.15B
est: 8.33B (+57.8%)
|
10.59B
est: 9.30B (+13.9%)
|
7.03B
est: 10.75B (-34.6%)
|
9.32B
est: 11.86B (-21.4%)
|
12.97B
est: 13.83B (-6.2%)
|
13.94B
13.82B – 14.07B
+0.8% YoY
|
15.51B
14.98B – 15.79B
+11.2% YoY
|
17.41B
16.70B – 18.06B
+12.3% YoY
|
| Net Income |
312.86M
est.
|
1.42B
est.
|
2.98B
est.
|
8.98B
est.
|
226.06M
est.
|
293.83M
est.
|
740.85M
est: 46.15M (+1,505.2%)
|
615.00M
est: 1.14B (-46.1%)
|
1.26B
est: 2.42B (-48.0%)
|
1.36B
est: 1.49B (-8.7%)
|
1.01B
est: 1.56B (-35.5%)
|
2.05B
est: 1.23B (+67.6%)
|
2.63B
est: 2.46B (+6.9%)
|
2.76B
est: 3.35B (-17.6%)
|
3.24B
est: 3.29B (-1.6%)
|
4.79B
est: 3.82B (+25.3%)
|
2.54B
est: 4.68B (-45.7%)
|
931.40M
est: 2.30B (-59.5%)
|
1.95B
est: 1.02B (+90.6%)
|
2.39B
est: 1.96B (+22.1%)
|
4.45B
est: 2.75B (+61.8%)
|
6.06B
est: 5.44B (+11.4%)
|
11.40B
est: 7.07B (+61.2%)
|
8.84B
est: 7.89B (+12.0%)
|
4.71B
est: 4.91B (-4.0%)
|
5.47B
est: 5.77B (-5.1%)
|
7.38B
est: 9.02B (-18.2%)
|
12.77B
12.00B – 13.54B
+41.6% YoY
|
14.15B
13.04B – 16.69B
+10.8% YoY
|
18.23B
16.71B – 19.74B
+28.8% YoY
|
| SGA |
466.03M
est.
|
1.96B
est.
|
4.14B
est.
|
12.46B
est.
|
313.73M
est.
|
386.14M
est.
|
—
est: 60.65M (-100.0%)
|
—
est: 1.59B (-100.0%)
|
—
est: 1.93B (-100.0%)
|
-142.70M
est: 1.39B (-110.3%)
|
-240.30M
est: 1.70B (-114.2%)
|
—
est: 2.32B (-100.0%)
|
3.75B
est: 2.69B (+39.1%)
|
3.71B
est: 4.02B (-7.7%)
|
7.70B
est: 9.26B (-16.9%)
|
9.20B
est: 10.64B (-13.5%)
|
5.87B
est: 10.71B (-45.1%)
|
6.47B
est: 10.97B (-41.0%)
|
7.18B
est: 13.48B (-46.7%)
|
7.60B
est: 13.64B (-44.3%)
|
8.12B
est: 16.37B (-50.4%)
|
9.37B
est: 18.77B (-50.1%)
|
10.32B
est: 19.98B (-48.4%)
|
11.97B
est: 22.30B (-46.3%)
|
13.10B
est: 25.78B (-49.2%)
|
17.32B
est: 14.20B (+22.0%)
|
20.07B
est: 14.94B (+34.3%)
|
16.69B
16.55B – 16.84B
+11.7% YoY
|
18.56B
17.93B – 18.90B
+11.2% YoY
|
20.84B
19.99B – 21.62B
+12.3% YoY
|
| EPS |
1.23
est.
|
1.80
est.
|
1.03
est.
|
0.20
est.
|
0.61
est.
|
0.91
est.
|
2.96
est: 6.18 (-52.1%)
|
2.46
est: 4.52 (-45.6%)
|
5.05
est: 9.60 (-47.4%)
|
5.43
est: 12.12 (-55.2%)
|
4.01
est: 12.26 (-67.3%)
|
8.22
est: 16.89 (-51.3%)
|
10.48
est: 19.61 (-46.6%)
|
10.99
est: 24.51 (-55.2%)
|
12.82
est: 30.71 (-58.3%)
|
18.96
est: 41.32 (-54.1%)
|
10.07
est: 13.00 (-22.5%)
|
3.69
est: 5.75 (-35.9%)
|
7.71
est: 7.95 (-3.0%)
|
9.49
est: 9.98 (-4.9%)
|
17.61
est: 17.22 (+2.3%)
|
23.99
est: 26.18 (-8.4%)
|
45.01
est: 46.20 (-2.6%)
|
34.85
est: 37.34 (-6.7%)
|
18.58
est: 20.72 (-10.3%)
|
21.57
est: 22.73 (-5.1%)
|
29.08
est: 35.77 (-18.7%)
|
49.87
47.31 – 53.36
+39.4% YoY
|
59.63
51.40 – 65.79
+19.6% YoY
|
71.00
65.86 – 77.82
+19.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
7.72B
OE per share TTM
30.44
Owner's Yield
2.00%
Maintenance CapEx ratio
128.08%
Maint CapEx / Avg PPE
49.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.03% | 66.9K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.02% | 3.01M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.02% | 1.25M | 0.17% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.02% | 1.25M | 0.17% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.02% | 267.3K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.02% | 602.9K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.02% | 29.75M | 0.06% |
| 8 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.02% | 111.4K | 0.40% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.01% | 420.5K | 0.10% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.01% | 236.5K | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
975.2K
Shares Outstanding
253.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Premchand Godha A. | Executive Chairman | 135M | male |
| Ajit Kumar Bhanwarlal Jain | Chief Financial Officer, MD & Executive Director | 98M | male |
| Pranay Godha | Chief Executive Officer, MD & Executive Director | 90M | male |
| Prashant Premchand Godha | Executive Director | 70M | male |
| Pawan Kothari | Vice President of Operations | — | male |
| Harish Kamath | Compliance Officer, Corporate Counsel & Company Secretary | — | male |
| Ashok Kumar | President of R&D - Chemicals | — | — |
| Saidutta Nanda | President of Human Resources | — | male |
| Sunil Ghai | President of Marketing | — | male |
| Vishnu Saran Singh Kushwaha | Vice President of Technical | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IPCALAB.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
